Trials / Recruiting
RecruitingNCT06390709
PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,100 (estimated)
- Sponsor
- Scipher Medicine · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Lab Collection Only | 2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study. |
Timeline
- Start date
- 2024-04-08
- Primary completion
- 2025-06-30
- Completion
- 2025-12-31
- First posted
- 2024-04-30
- Last updated
- 2024-04-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06390709. Inclusion in this directory is not an endorsement.